Are professional guidelines making Patent Attorneys too cautious on AI?

​
February 19, 2026

As I write this, the FTSE 100 company Relx’s share price has declined 50% in six months. Although Relx may be unfamiliar, its company Lexis Nexis is well known in the legal sector. And in this case, the market fears might be correct; 2026 is set to be the year of AI for patent attorneys. But there’s a complicating factor, especially for European patent firms. The epi issued professional guidelines on the use of AI (“AI Guidelines”) that patent attorneys must follow in their work. The epi is the professional body for European Patent Attorneys and covers 14,4351 qualified European Patent Attorneys. I’m going to take a look at some of the key points of the AI Guidelines2 from the epi. I’ll show how it is just the start and I’ll explain why Hybrid Intelligence is the future.

AI, surely that just makes stuff up

Many European patent attorneys view these AI Guidelines as an additional barrier to the use of AI. The AI Guidelines understandably focus on risk and some European patent attorneys use them as a reason to resist AI completely.  But that misses the point. The AI Guidelines are a starting point to ensure AI is used responsibly and without jeopardising valuable IP.

We’re all aware of high-profile AI fails; hallucinated case law and quotations from documents that don’t exist. Generative AI does have risks, and those risks can result in work which isn’t just low quality, but negligent. And here’s where an open mind on the AI Guidelines helps. They aren’t a barrier but a set of guard rails representing a minimum for an acceptable service.

To excel with AI, you must do more than just use AI and follow the AI Guidelines. At EIP, we have Hybrid Intelligence, where the combination of attorney and AI is genuinely better than either alone. I know this from experience, new ways of working with AI are improving my work products.

To give an example, a couple of years ago, I posted on LinkedIn how an AI patent search had found me a relevant patent in minutes. It became one of my most viewed posts, helped by a debate about how AI could not compare to a carefully crafted Boolean search in full text.  The undertone was clear that AI was somehow inferior, despite providing faster results than was possible before.

So, let’s look at some of the AI Guidelines in more detail and see how they are just a starting point for EIP’s Visser AI service.

Client permission is required using AI on client work. (Guideline 4)

I’ll start with this because it’s arguably the point which has the greatest impact. It’s vital that clients know AI is being used and agree to its use. But the underlying message is that AI is a shortcut and some time-pressured patent attorneys might try and sneak it in to get something done more quickly. It’s set the conversation up the wrong way round.  What about all the many clients who want their patent attorneys to leverage AI to improve work products and outcomes?

That’s the motivation behind our Visser AI service, which responds to the market demand for patent attorneys to use AI. We know that many clients want their attorney to use AI. And those clients are sophisticated, they want to see a reduction in cost and a fantastic work product. Hybrid Intelligence can deliver that by the attorney working with AI in ways that were not previously possible.

Patent Attorneys must check the output of AI. (Guideline 3b)

Frankly, this should be a given, although the legal horror stories show how that often isn’t the case. Again, we see how the underlying feeling is that AI will make mistakes that prejudice the client. If you have to check the work, how can it possibly be any better than just doing it yourself in the first place?  

This is where Hybrid Intelligence comes in, of course we check the output but we also apply our judgement and know-how to influence the AI for the best results. It’s not a case of prompting and reading the answer to make sure it’s free of hallucinations but understanding why that answer was given and using that understanding to enhance the results.  AI is not intelligent in the human sense, but it can certainly appear so.  By understanding this and using it to our advantage, we can get amazing results.

Any AI used for patent work cannot retain client data and cannot use client data for training. (Guideline 2a)

Protecting confidential information is central to life as a patent attorney.  EIP has had an ISO27001 accredited Information Security Management System in place for many years to support this. We have annual training on best security practices. Even without this in the AI Guidelines, I’m sure every attorney would not dream of allowing client information to be inadvertently disclosed.  

But few people understand just how much data AI services can and do use. Many people don’t understand that their data is retained and used for training AI behind the scenes. Take Gemini, for instance.  You can only get true zero data retention with an enterprise subscription; a paid subscription alone does not provide this guarantee.

Specialist Patent AI can guarantee zero retention, but sometimes a combination of AI tools can give even better results than is possible with other services. EIP’s Tech and AI team have been at the forefront of this assessment, ensuring a suite of tools is available with zero data retention. For example, it won’t be long before AI agents are preparing and filing patent applications at patent offices.

The AI Guidelines are a starting point, not a barrier.

So, the AI guidelines are not a barrier but a minimum standard. Clients will increasingly expect more. Visser AI’s forward-deployed patent attorneys are already pushing the boundaries of what’s possible with AI, exploring new ways of working to improve results and efficiency.  This is more than a library of prompts.  To give an example, we know how context influences output so we control context for the best results.

Get in touch with Laurence Brown, if you’d like to learn more about Visser AI and Hybrid Intelligence, we can show you how it can improve outcomes and allow your patent budget to go further. It’s all fully compliant with the AI Guidelines and takes it to the next level.

‍

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​